A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
NCT01427816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2013-10-30
Summary
To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.
Conditions
- Dry Eye Syndromes
Interventions
- DRUG
-
KCT-0809
- DRUG
-
KCT-0809
- DRUG
Sponsors & Collaborators
-
Kissei Pharmaceutical Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Katsumi Hontani · Clinical Development Department, Kissei pharmaceutical Co., Ltd.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Japan
More Related Trials
-
Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes
NCT00721656 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503176 ·Status: TERMINATED ·Phase: PHASE3
-
Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT01189032 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
NCT04084483 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
NCT02092207 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
NCT04092907 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
NCT03216096 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
NCT03088605 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease
NCT01562795 ·Status: COMPLETED ·Phase: NA
-
Study of OT202 in Treating Moderate to Severe Dry Eye
NCT06435182 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye
NCT04633213 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers
NCT03662971 ·Status: COMPLETED ·Phase: PHASE1
-
YM-101 Eye Drops in the Treatment of Dry Eye Syndrome
NCT06792903 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
NCT04104997 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
NCT04139122 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
NCT06717152 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing the Quality of Topical Autologous Serum in Different Etiologies of Dry Eye Syndrome
NCT02774707 ·Status: UNKNOWN
-
[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001
NCT05017870 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome
NCT01670357 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease
NCT04679883 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of ST-100 as Treatment for Dry Eye Disease
NCT05241470 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
NCT01843894 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
NCT05759208 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
NCT01468168 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
NCT05403827 ·Status: COMPLETED ·Phase: PHASE3